|
SAN DIEGO, November 1, 2007
LA JOLLA PHARMACEUTICAL COMPANY REPORTS THIRD QUARTER AND YEAR-TO-DATE FINANCIAL RESULTS
SAN DIEGO, October 31, 2007
LA JOLLA PHARMACEUTICAL COMPANY TO PRESENT MARCH 2007 RIQUENT® INTERIM ANTIBODY DATA AT TWO LEADING MEDICAL MEETINGS
SAN DIEGO, September 13, 2007
LA JOLLA PHARMACEUTICAL COMPANY TO PRESENT AT A.G. EDWARDS AND UBS INVESTOR CONFERENCES
SAN DIEGO, August 2, 2007
LA JOLLA PHARMACEUTICAL COMPANY REPORTS SECOND QUARTER AND YEAR-TO-DATE FINANCIAL RESULTS
SAN DIEGO, July 31, 2007
LA JOLLA PHARMACEUTICAL COMPANY TO PRESENT AT CANACCORD ADAMS GLOBAL GROWTH CONFERENCE
SAN DIEGO, June 7, 2007
LA JOLLA PHARMACEUTICAL COMPANY TO PRESENT AT NEEDHAM HEALTHCARE CONFERENCE
SAN DIEGO, May 24, 2007
LA JOLLA PHARMACEUTICAL COMPANY REPORTS RIQUENT® WELL TOLERATED IN THREE STUDIES AT INTERNATIONAL LUPUS CONGRESS
SAN DIEGO, May 10, 2007
LA JOLLA PHARMACEUTICAL COMPANY NAMES NIV CAVIAR CHIEF BUSINESS AND FINANCIAL OFFICER
SAN DIEGO, May 3, 2007
LA JOLLA PHARMACEUTICAL COMPANY REPORTS FIRST QUARTER FINANCIAL RESULTS
SAN DIEGO, April 26, 2007
LA JOLLA PHARMACEUTICAL RECEIVES RIQUENT® COMPOSITION OF MATTER PATENTS IN EUROPE AND CHINA
SAN DIEGO, April 10, 2007
LA JOLLA PHARMACEUTICAL COMPANY ANNOUNCES EXERCISE OF FULL OVER-ALLOTMENT OPTION
SAN DIEGO, March 29, 2007
LA JOLLA PHARMACEUTICAL COMPANY ANNOUNCES PRICING OF COMMON STOCK OFFERING
SAN DIEGO, March 20, 2007
LA JOLLA PHARMACEUTICAL COMPANY ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK
SAN DIEGO, March 20, 2007
LA JOLLA PHARMACEUTICAL PROVIDES UPDATE ON INTERIM ANTIBODY RESULTS FROM RIQUENT® LUPUS PHASE 3 TRIAL
SAN DIEGO, March 8, 2007
LA JOLLA PHARMACEUTICAL ANNOUNCES POSITIVE INTERIM ANTIBODY RESULTS FROM RIQUENT® LUPUS PHASE 3 TRIAL
SAN DIEGO, March 1, 2007
LA JOLLA PHARMACEUTICAL COMPANY REPORTS FOURTH QUARTER AND YEAR-TO-DATE FINANCIAL RESULTS
SAN DIEGO, February 8, 2007
LA JOLLA PHARMACEUTICAL COMPANY TO PRESENT AT
BIO CEO & INVESTOR CONFERENCE
SAN DIEGO, February 1, 2007
LA JOLLA PHARMACEUTICAL ANNOUNCES CONTINUED ENROLLMENT PROGRESS AND ENHANCEMENTS TO INTERNATIONAL PHASE 3 RIQUENT® STUDY
|